United States-based Senores Pharmaceuticals, Inc announced on Monday that it has launched its Nicardipine Hydrochloride Capsules USP, 20mg and 30mg, a bioequivalent and therapeutically equivalent to Chiesi USA's Cardene Capsules, 20mg and 30mg, in the United States.

Burel Pharmaceuticals, LLC is to market the product.

The product is indicated for the management of patienrs with chronic stable angina (effort-associated angina) and for the treatment of hypertension.

The company has received a Competitive Generic Therapy (CGT) designation for Nicardipine Hydrochloride Capsules USP, 20mg and 30mg. With this approval, the company is eligible for 180 days of CGT exclusivity upon commercial marketing.